Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR Newswire VICTORIA, BC, Oct. 31, 2024 VICTORIA, BC, Oct. 31, 2024 /PRNewswire/...
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR Newswire VICTORIA, BC, Oct. 28, 2024 VICTORIA, BC, Oct. 28, 2024 /PRNewswire/...
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis PR Newswire VICTORIA, BC, Oct. 15, 2024 Publication...
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC, Oct. 10, 2024 VICTORIA, BC, Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...
Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA, BC, Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.33 | -6.6265060241 | 4.98 | 4.98 | 4.41 | 13283 | 4.70334859 | CS |
| 4 | 0 | 0 | 4.65 | 5.45 | 3.89 | 32178 | 4.56748931 | CS |
| 12 | 1.24 | 36.3636363636 | 3.41 | 5.45 | 3.07 | 32126 | 4.08172993 | CS |
| 26 | 0.91 | 24.3315508021 | 3.74 | 5.45 | 3.07 | 23236 | 3.90441002 | CS |
| 52 | -0.95 | -16.9642857143 | 5.6 | 7.64 | 3.07 | 33095 | 4.3391422 | CS |
| 156 | 2.73 | 142.1875 | 1.92 | 9.1 | 0.8 | 27662 | 4.25300364 | CS |
| 260 | -3.1 | -40 | 7.75 | 9.1 | 0.8 | 25253 | 4.23464231 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
